XML 40 R27.htm IDEA: XBRL DOCUMENT v3.22.2
Collaboration Agreements - Additional Information (Detail)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended 50 Months Ended
Oct. 15, 2021
USD ($)
Apr. 02, 2018
Apr. 30, 2018
USD ($)
Target
$ / shares
shares
Feb. 28, 2018
USD ($)
Jun. 30, 2022
USD ($)
Jun. 30, 2021
USD ($)
Jun. 30, 2022
USD ($)
Jun. 30, 2021
USD ($)
Mar. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Proceeds from issuance of ordinary shares, net of offering costs             $ 51,464      
Collaboration revenue recognized         $ 375 $ 2,776 2,125 $ 2,776    
Collaboration and license agreement, deferred revenue current         37,466   37,466     $ 37,098
Takeda [Member]                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Fund receivable for research and preclinical activities     $ 60,000              
Up-front consideration received     $ 110,000              
Collaboration And License Agreement [Member] | Category One Programs [Member]                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Percentage of global costs and potential profits sharing ratio     50.00%              
Collaboration And License Agreement [Member] | Takeda [Member]                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Upfront payment under collaboration agreement     $ 110,000              
Collaboration and license agreement month and year     2018-02              
Fund receivable for research and preclinical activities     $ 60,000              
Research term under collaboration and license agreement     4 years              
Collaboration agreement commencement date   Apr. 02, 2018                
Collaboration agreement termination period   180 days                
Collaboration And License Agreement [Member] | Takeda [Member] | Minimum [Member]                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Collaboration agreement, committed cash       $ 230,000            
Collaboration And License Agreement [Member] | Takeda [Member] | Category One Programs [Member]                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Percentage of global costs and potential profits sharing ratio     50.00%              
Collaboration and License Agreement Date Oct. 15, 2021                  
Collaboration revenue recognized         300 $ 2,800 1,900 $ 2,800 $ 79,800  
Collaboration and license agreement, deferred revenue         112,700   112,700     114,200
Collaboration and license agreement, deferred revenue current         $ 37,500   $ 37,500     $ 37,100
Collaboration And License Agreement [Member] | Takeda [Member] | Category Two Programs [Member]                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Fund receivable for research and preclinical activities     $ 60,000              
Research term under collaboration and license agreement     4 years              
Maximum targets for preclinical programs | Target     6              
Option to reach maximum targets for preclinical programs             any one time      
Collaboration-budgeted research and preclinical expenses $ 22,500                  
Collaboration and Share Purchase Agreements [Member] | Takeda [Member]                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Shares issued under equity agreement | shares     1,096,892              
Purchase price per share | $ / shares     $ 54.70              
Proceeds from issuance of ordinary shares, net of offering costs     $ 60,000              
Equity investment agreement official closure month and year     2018-04